Carl Dambkowski Sells 4,085 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,085 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total value of $191,749.90. Following the completion of the transaction, the insider now owns 255,348 shares in the company, valued at $11,986,035.12. The trade was a 1.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.76, for a total value of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.12, for a total transaction of $394,034.80.

Apogee Therapeutics Trading Up 1.3 %

Shares of NASDAQ APGE traded up $0.62 during trading hours on Friday, hitting $47.77. 248,646 shares of the company traded hands, compared to its average volume of 266,873. The company’s 50 day moving average price is $49.13 and its 200 day moving average price is $48.57. Apogee Therapeutics, Inc. has a 12 month low of $27.05 and a 12 month high of $72.29. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -19.74 and a beta of 2.30.

Institutional Trading of Apogee Therapeutics

Several institutional investors have recently added to or reduced their stakes in APGE. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Apogee Therapeutics during the third quarter valued at $71,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after acquiring an additional 285 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Apogee Therapeutics during the second quarter worth approximately $143,000. Wexford Capital LP bought a new stake in shares of Apogee Therapeutics during the third quarter valued at approximately $230,000. Finally, Intech Investment Management LLC bought a new stake in shares of Apogee Therapeutics during the third quarter valued at approximately $300,000. Institutional investors own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on APGE. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Canaccord Genuity Group started coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price on the stock. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research report on Thursday, December 12th. Finally, Wedbush upped their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $89.71.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.